The high-stakes nature of cancer care, coupled with rapid scientific advancements, increasing payer and regulatory pressures, ...
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., March (GLOBE NEWSWIRE) -- Checkpoint ...
Triple-negative breast cancer, an aggressive type of breast cancer, accounts for 10% of all breast cancer cases in the United ...
BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati ...
Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback